High Definition Medicine for Solid Tumors Oncology

The present study aims to analyze different genetic, phenotypic, environmental, social and lifestyle characteristics of cancer patients who are going to start a first line of cancer treatment with palliative intent and their possible relationship with tumor response or tolerance to treatment. In this way, the aim is to identify a series of variables that allow a better selection of patients and oncological treatments.

Trial Details

NCT ID
NCT06590506
Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Status
RECRUITING
Cancer Type
Breast Cancer
Locations (sample)
  • A Coruña, A Coruña/ Galicia, Spain
  • Fuenlabrada, Madrid, Spain
  • Palma de Mallorca, Mallorca / Baleares, Spain
  • Pamplona, Navarre, Spain
  • Seville, Sevilla/ Andalucia, Spain

Key Eligibility Criteria

  • Confirmed diagnosis of oncological disease of solid origin, candidate for first-line treatment (TREATMENT VIRGIN FOR METASTIC DISEASE).
  • Advanced tumor stage (III or IV) not a candidate for treatment with curative intent.
  • Preference will be given to the following pathologies and sub-types:
  • Women with hormone-positive, HER2-negative breast cancer who will receive a CDK4/6 inhibitor plus a hormone inhibitor. o Women with lung cancer of …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →